Novel Dy incorporated Ca3Y2B4O12 phosphor: Insights into the structure, broadband emission, photoluminescence and cathodoluminescence characteristics

This study reports cathodoluminescence (CL) and photoluminescence (PL) properties of undoped borate Ca3Y2B4O12 and Ca3Y2B4O12:x Dy3+ (x = 0.5, 1, 2, 3, 5, and 7) synthesized by gel combustion method. Micro-X-Ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), CL and PL under electron beam and 359 nm pulse laser excitation, respectively were used to investigate characterization and luminescence studies of synthesized samples in the visible wavelength. As-prepared samples match the standard Ca3Y2BO4 phase that belongs to the orthorhombic system with space group Pnma (62) based on XRD results. Under electron beam excitation, this borate host shows a broad band emission from about 250 to 450 nm, peaked at 370 nm which is attributed to NBHOC. All as-prepared phosphors exhibited the characteristic PL and CL emissions of Dy3+ ions corresponding to 4F9/2→6HJ transitions when excited with laser at 359 nm. The CL emission spectra of phosphors were identical to those of the PL spectra. Concentration quenching occurred when the doping concentration was 1 mol% in both the CL and PL spectra. The underlying reason for the concentration quenching phenomena observed in the discrete orange-yellow emission peaked at 574 nm of Dy3+ ion-doped Ca3Y2B4O12 phosphor is also discussed. According to these data, we can infer that this new borate can be used as a yellow emitting phosphor in solid-state illumination.This work was supported by İzmir Bakırçay University Scientific Research Projects Coordination Unit, under grant number GDM.2021.003 and the Spanish Project entitled Rock-Eaters, PID-2019-105469RB-C22.Peer reviewe

Evaluation of a quality improvement intervention to reduce anastomotic leak following right colectomy (EAGLE): pragmatic, batched stepped-wedge, cluster-randomized trial in 64 countries

Background Anastomotic leak affects 8 per cent of patients after right colectomy with a 10-fold increased risk of postoperative death. The EAGLE study aimed to develop and test whether an international, standardized quality improvement intervention could reduce anastomotic leaks. Methods The internationally intended protocol, iteratively co-developed by a multistage Delphi process, comprised an online educational module introducing risk stratification, an intraoperative checklist, and harmonized surgical techniques. Clusters (hospital teams) were randomized to one of three arms with varied sequences of intervention/data collection by a derived stepped-wedge batch design (at least 18 hospital teams per batch). Patients were blinded to the study allocation. Low- and middle-income country enrolment was encouraged. The primary outcome (assessed by intention to treat) was anastomotic leak rate, and subgroup analyses by module completion (at least 80 per cent of surgeons, high engagement; less than 50 per cent, low engagement) were preplanned. Results A total 355 hospital teams registered, with 332 from 64 countries (39.2 per cent low and middle income) included in the final analysis. The online modules were completed by half of the surgeons (2143 of 4411). The primary analysis included 3039 of the 3268 patients recruited (206 patients had no anastomosis and 23 were lost to follow-up), with anastomotic leaks arising before and after the intervention in 10.1 and 9.6 per cent respectively (adjusted OR 0.87, 95 per cent c.i. 0.59 to 1.30; P = 0.498). The proportion of surgeons completing the educational modules was an influence: the leak rate decreased from 12.2 per cent (61 of 500) before intervention to 5.1 per cent (24 of 473) after intervention in high-engagement centres (adjusted OR 0.36, 0.20 to 0.64; P < 0.001), but this was not observed in low-engagement hospitals (8.3 per cent (59 of 714) and 13.8 per cent (61 of 443) respectively; adjusted OR 2.09, 1.31 to 3.31). Conclusion Completion of globally available digital training by engaged teams can alter anastomotic leak rates. Registration number: NCT04270721 (http://www.clinicaltrials.gov)